Dynavax reports Q4 preliminary HEPLISAV-B net product revenue $35M

Preliminary HEPLISAV-B Net Product Revenue for the fourth quarter and full year 2022 were approximately $35 million and $126 million, respectively, representing quarterly and annual growth of 105% and 104% compared to Q4 2021 and full year 2021, respectively. Preliminary CpG 1018 adjuvant Net Product Revenue for the fourth quarter and full year 2022 were approximately $147 million and $588 million, respectively, representing the successful completion of all pandemic adjuvant delivery obligations under existing commercial supply agreements. Approximately $624 million in estimated Cash and Cash Equivalents, and Marketable Securities as of December 31, 2022.